Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) causes almost as much weight loss as ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

But patients taking GLP-1 drugs did have a greater likelihood of retained gastric contents and of aborted upper endoscopies, ...

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few episodes of disease exacerbation and resulted in a significant decrease in ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

For the first time in decades, the prevalence of obesity has not increased in the USA, according to the latest National Health and Nutrition Examination Survey from the US Centers for Disease Control ...

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with ... from lack of willpower and shed light on underlying mechanisms that can be targeted by pharmacotherapy.” ...

This is a very large market opportunity, but the thing is that GLP-1R agonists ... an LPA1 receptor [LPA1R] agonist drug for the treatment of patients with IPF in the ongoing phase 1 study.